scholarly journals Correlation of Serum Cystatin C with Atherogenic indices in obese individuals

2015 ◽  
Vol 3 (02) ◽  
Author(s):  
K Deepa ◽  
Sudhir . ◽  
Shubha Jayaram ◽  
S Meera ◽  
M H Rahul
Keyword(s):  
Cardiovascular Disease ◽  
Cystatin C ◽  
Risk Index ◽  
Serum Levels ◽  
Atherogenic Index ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Atherogenic Index Of Plasma ◽  
Atherogenic Indices ◽  
Study Population

Introduction: Human obesity is strongly associated with cardiovascular disease. Cystatin C is a naturally occurring protease inhibitor and marker of cardiovascular disease. The atherogenic indices are used as an index for cardiac risk stratification. Objectives: To estimate the serum levels of Cystatin C in individuals with normal BMI, and obese, aged between 20-39 Yrs and to compare the levels of Cystatin C among these individuals and to correlate the levels of serum Cystatin C with atherogenic index of plasma and other indices. Methodology: The study population was taken from healthy volunteers of Mysore city, aged between 20-39 years of either sex. The study population was divided into 2 groups based on BMI. Each group contains sample size of 60. Fasting serum sample was analyzed for Total Cholesterol, TG, LDL-Cholesterol and HDL cholesterol by enzymatic method and serum Cystatin-C by immune-turbidimetric method using auto-analyser. Statistical Analysis: Analysis of Variance [ANOVA] was used to compare the serum levels of Cystatin C in the two groups. To correlate the serum Cystatin C with atherogenic indices for predicting the cardiovascular risk factors, Pearson’s correlation co-efficient was worked out. Results: The mean serum cystatin C levels in normal BMI group are 0.7±0.03 mg/L, and in Obese group 1.15±0.09 mg/(p value less than 0.001).In the study serum Cystatin C showed a positive correlation with serum triglycerides (r=0.7), Atherogenic index of plasma(AIP ) (r=0.80), TCHOL: HDL (Castelli’s Risk Index I) (r=0.71), HDL: LDL(Castelli’s Risk Index II) (r=0.70) respectively and Atherogenic coefficient (AC) {(NonHDLc)/HDLc}( r=0.60) and negative correlation with serum HDL(r=-0.52) Conclusion: Several indices had been derived from lipid profiles to establish an index for predicting the risk of having coronary event. The atherogenic index of plasma was strongly correlated with the Cystatin C, hence AIP can be used as better index for predicting the preclinical cardiovascular disease because of cost effectiveness in estimation of Cystatin C.

Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia

2021 ◽  
pp. 026988112110264
Author(s):  
Sinay Onen ◽  
Ibrahim Taymur
Keyword(s):  
Cardiovascular Disease ◽  
Serum Lipid ◽  
Risk Index ◽  
Atherogenic Index ◽  
Healthy Controls ◽  
Cvd Risk ◽  
Atherogenic Index Of Plasma ◽  
Atherogenic Indices ◽  
And Control ◽  
Drug Free

Background: Schizophrenia is known to be accompanied with increased cardiovascular mortality, which causes reduced life expectancy. Aim: The aim of the current study was to investigate if atherogenic index of plasma (AIP) could be a good marker in assessing cardiovascular disease (CVD) risk in patients with schizophrenia. Methods: Patients with schizophrenia ( n = 328) and healthy controls ( n = 141) were recruited. Schizophrenia patients were evaluated according to the presence of antipsychotic (AP) drug use as AP(+)Sch group and AP(−)Sch group. Atherogenic indices, such as AIP, Castelli’s risk index-I (CRI-I), Castelli’s risk index-II (CRI-II), and atherogenic coefficient (AC), were calculated according to the laboratory examination of serum lipid parameters. Results: According to the comparison of serum lipid levels, triglyceride (TG) levels were found to be highest and high-density lipoprotein–cholesterol levels were lowest in AP(+)Sch group than AP(−)Sch group and control group (CG) ( p < 0.001). AIP, CRI-I, and CRI-II scores were found to be significantly higher in AP(+)Sch group than AP(−)Sch group, and in AP(−)Sch than healthy controls ( p < 0.001). Mean AC scores were higher in AP(+)Sch group than both AP(−)Sch and CG and were similar in AP(−)Sch and control subjects ( p < 0.001). According to the correlation analysis, AIP scores were positively correlated with duration of disease ( r = 0.235; p = 0.002) and age ( r = 0.226; p = 0.003) in AP(+)Sch group but not in drug-free subjects. In all groups, atherogenic indices of CRI-I, CRI-II, and AC scores were found to be positively correlated with AIP scores ( p < 0.001). Conclusion: Our results suggest that AIP is an easily calculable and reliable marker for determining the CVD risk in both drug-free schizophrenia patients and patients under AP treatment.

scholarly journals Serum Cystatin C, a Sensitive Marker of Renal Function and Cardiovascular Disease, Decreases After Smoking Cessation

2019 ◽  
Vol 1 (12) ◽  
pp. 623-627
Author(s):  
Masafumi Funamoto ◽  
Kana Shimizu ◽  
Yoichi Sunagawa ◽  
Yasufumi Katanasaka ◽  
Yusuke Miyazaki ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Smoking Cessation ◽  
Renal Function ◽  
Cystatin C ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Sensitive Marker

scholarly journals PENGARUH PEMBERIAN KONTRAS MEDIA NON IONIK LOW OSMOLAR INTRA VENA TERHADAP KADAR CYSTATIN–C SERUM PADA ORYCTALAGUS CUNICULUS

1970 ◽  
Vol 15 (2) ◽  
Author(s):  
Ariyo Sakso Bintoro ◽  
Soetojo Soetojo ◽  
Doddy M Soebadi
Keyword(s):  
Cystatin C ◽  
Sandwich Elisa ◽  
Intervention Group ◽  
Serum Levels ◽  
Control Group ◽  
Test Results ◽  
Elisa Method ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Ionic Contrast

Objective: To measure effects of low osmolar non ionic contrast media on cystatin–C serum levels on different days after administration. Material and Method: Twenty-two oryctalagus cuniculus were divided into two groups of 11 subjects, each subject receiving intravenous injection of low osmolar non ionic contrast or a placebo solution (NaCl 0,9%). Cystatin-C serum levels of each subject were measured before injection, on days 1, 3, 7, and 10. Cystatin–C serum levels were determined with a sandwich ELISA method. Statistical analysis was performed with t–test. Results: Mean cystatin–C serum levels before injection was 0,00337 ± 0,00101 mg/L. Means from days 1, 3, 7, and 10 after injections were 0,00498 ± 0,00153 mg/L; 0,00565 ± 0,00247 mg/L; 0,00468 ± 0,00157, and 0,00339 ± 0,00188 mg/L respectively. Conclusion: Increase in serum cystatin–C levels on days 1, 3, and 7 was significant. On the 10th day no significant escalation was observed. Compared to the control group, there were significant differences in serum cystatin–C increase on days 1 and 3 in the intervention group, but no significant differences 7 and 10 days after injection.

scholarly journals Cystatin C at Admission in the Intensive Care Unit Predicts Mortality among Elderly Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Maria Aparecida Dalboni ◽  
Daniel de Oliveira Beraldo ◽  
Beata Marie Redublo Quinto ◽  
Rosângela Blaya ◽  
Roberto Narciso ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Elderly Patients ◽  
Cystatin C ◽  
Independent Predictor ◽  
Kidney Injury ◽  
Roc Curves ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin

Introduction. Cystatin C has been used in the critical care setting to evaluate renal function. Nevertheless, it has also been found to correlate with mortality, but it is not clear whether this association is due to acute kidney injury (AKI) or to other mechanism. Objective. To evaluate whether serum cystatin C at intensive care unit (ICU) entry predicts AKI and mortality in elderly patients. Materials and Methods. It was a prospective study of ICU elderly patients without AKI at admission. We evaluated 400 patients based on normality for serum cystatin C at ICU entry, of whom 234 (58%) were selected and 45 (19%) developed AKI. Results. We observed that higher serum levels of cystatin C did not predict AKI ( versus  mg/L; ). However, it was an independent predictor of mortality, H.R. = 6.16 (95% CI 1.46–26.00; ), in contrast with AKI, which was not associated with death. In the ROC curves, cystatin C also provided a moderate and significant area (0.67; ) compared to AKI (0.47; ) to detect death. Conclusion. We demonstrated that higher cystatin C levels are an independent predictor of mortality in ICU elderly patients and may be used as a marker of poor prognosis.

scholarly journals Cystatin-C as Novel Marker of Neonatal Hyperbilirubinemia, in Al-Najaf City, Iraq

2021 ◽  
Vol 2 (2) ◽  
pp. 64-70
Author(s):  
Sarah Ali Aljazaeri
Keyword(s):  
Cystatin C ◽  
Serum Levels ◽  
Neonatal Hyperbilirubinemia ◽  
Cysteine Protease Inhibitor ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Male And Female ◽  
Healthy Group ◽  
The Family ◽  
Apparently Healthy

Neonatal hyperbilirubinemia results from a readiness for the bilirubin production in neonates and limited their ability to excrete it. The diagnosis of hyperbilirubinemia based on yellow discoloration of the skin and whiteness of eyes, idle in the child's movement and the lack of lactation. The baby seems sick or is difficult to awaken. Serum cystatin-C, is a low molecular protein that belongs to the family of cysteine protease inhibitor, was proposed as an endogenous filtration marker. In this study sixty neonatal patients suffering from hyperbilirubinemia (35 males,25female) were collected from prematurity unit (PU) in Al-Zahra Educational Hospital/Al-Najaf Al-Ashraf during the period from August,2020 to February,2021. A group of 20 randomly (12male, 8female) selected apparently healthy group. After diagnosis of hyperbilirubinemia, the patients were divided into three groups according to age (1-3), (4-7) and (7-9) days.  The result reveals that significant increase (p<0.05) in serum cystatin-C in neonatal hyperbilirubinemia as compared with healthy group. The result of study reveals no significant increase(p<0.05) in serum levels of cystatin-C, while the study shows a significant increase (p<0.05) between male and female in serum levels of bilirubin. 

scholarly journals Serum Cystatin C, Kidney Injury Molecule-1, Neutrophil Gelatinase-Associated Lipocalin, Klotho and Fibroblast Growth Factor-23 in The Early Prediction of Acute Kidney Injury Associated With Sepsis in a Chinese Emergency Cohort Study

2021 ◽  
Author(s):  
Yuanyuan Pei ◽  
Guangping Zhou ◽  
Pengfei Wang ◽  
Fang'e Shi ◽  
Xiaolu Ma ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Fibroblast Growth Factor 23 ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Kidney Injury Molecule 1 ◽  
Fgf 23

Abstract Background: Acute kidney injury (AKI) was a common and critical complication of sepsis, and is associated with unacceptable morbidity and mortality. Current diagnostic criteria for AKI was insensitive for early detection. Novel biomarkers included cystatin C, KIM-1, NGAL, klotho and FGF-23 which can predict AKI earlier may allow immediate interventions. We aimed to determine the diagnostic performance of these biomarkers for detecting AKI in sepsis patients.Methods: This prospective observational study was conducted from May 2018 and November 2020, enrolling sequential 162 sepsis patients. AKI’s definition was according to 2012 KDIGO criteria and we divided patients into non-AKI (n=102) and AKI (n=60) groups. Serum levels of several AKI biomarkers were detected by ELISA. The relationship between biomarker levels on admission of AKI were analyzed and discrimination performances comparison were performed.Results: AKI incidence was up to 37.0% (60/162) during hospitalization. Compared with non-AKI group, both serum cystatin C, KIM-1, NGAL and FGF-23 were significantly elevated at admission in septic AKI patients. The areas under the receiver operating curves demonstrated that serum cystatin C had modest discriminative powers for predicting AKI after sepsis, and cystatin C combined with serum creatinine in the prediction of septic AKI increased the diagnostic sensitivity prominently.Conclusion: Serum cystatin C, KIM-1, NGAL and FGF-23 levels are both increased in septic AKI patients. Our study provides reliable evidence that cystatin C solely and combined with serum creatinine may accurately and sensitively predict septic AKI when patients on admission.

Association between serum cystatin C levels and cardiovascular disease in type 2 diabetic patients

2013 ◽  
Vol 71 (4) ◽  
pp. 438-442
Author(s):  
Sonia Triki ◽  
Ons Fekih ◽  
Ilhem Hellara ◽  
Fadoua Neffati ◽  
Wahiba Douki ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cystatin C ◽  
Diabetic Patients ◽  
Serum Cystatin C ◽  
Type 2 Diabetic Patients ◽  
Serum Cystatin ◽  
Type 2 Diabetic

scholarly journals Cystatin C and Iris: Advances in the Evaluation of Kidney Function in Critically Ill Dog

2021 ◽  
Vol 8 ◽  
Author(s):  
Fabiola de Oliveira Paes-Leme ◽  
Eliana M. Souza ◽  
Paulo Ricardo Oliveira Paes ◽  
Maderleine Geisa Gomes ◽  
Felipe Santos Muniz ◽  
...  
Keyword(s):  
Critically Ill ◽  
Cystatin C ◽  
Urine Output ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Daily Monitoring ◽  
Early Biomarker

Critically ill hospitalized dogs are subject to certain complications, being acute kidney injury (AKI) a common one. Early diagnosis is crucial, and Cystatin C (CysC) is a reliable and early biomarker. The International Society of Renal Interest (IRIS) states that AKI severity can be assessed by mild changes in creatinine serum levels or reduction of urine output that cannot be considered biomarkers of renal injury but failure or insufficiency. Twenty-eight dogs admitted to the Intensive Care Unit under risk factors for the development of AKI were evaluated. Blood samples were collected for determination of sCr and CysC at admission and after 24, 48, and 72 h. Urine output was measured by daily monitoring, measured by collection in a closed system. The results showed the incidence of AKI was 67.9% based on the IRIS criteria and 78.6% based on cystatin C in critically ill patients' dogs. The measurement of serum cystatin C immediately on admission to the ICU was superior in the early identification of patients with AKI when compared to the IRIS classification and serum creatinine in critically ill dogs.

Serum Cystatin C, Klotho, and Neutrophil Gelatinase-Associated Lipocalin in the Risk Prediction of Acute Kidney Injury after Acute Myocardial Infarction

2020 ◽  
Vol 10 (6) ◽  
pp. 374-381
Author(s):  
Yuanyuan Pei ◽  
Wen Chen ◽  
Xue Mao ◽  
Jihong Zhu
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase

<b><i>Background:</i></b> Patients with acute myocardial infarction (AMI) are at high risk for acute kidney injury (AKI). Novel biomarkers that can predict AKI after AMI may facilitate immediate interventions. Recently, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), and klotho have been established as novel AKI biomarkers. However, their effects have not been studied in patients presenting with AMI. In this study, we will measure the serum levels of these three biomarkers to find reliable biomarkers for early diagnosis of AKI in AMI patients. <b><i>Methods:</i></b> This prospective observational cohort study was conducted between May 2016 and November 2017. A total of 285 consecutive patients with AMI were enrolled. The study was approved by the institutional review board of Peking University People’s Hospital (No. 2016PHB 042-01). AKI was defined according to the KDIGO criteria in 2012. At admission, the clinical data of patients was collected and serum levels of several AKI biomarkers, including cystatin C, NGAL, and klotho, were measured by ELISA. The relationship between biomarker levels of AKI were analyzed and their discrimination performances were compared. <b><i>Results:</i></b> AKI incidence was 17.5% (50/285) during hospitalization. Compared to patients without AKI, the AKI group had higher mortality (20.0% vs. 0.4%,<i> p</i> &#x3c; 0.001) and tended to be older, had higher incidence of chronic kidney disease, severe cardiac function, more cardiac complications, larger doses of diuretics, and less use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker and statins. Moreover, AKI patients experienced an increase in serum cystatin C (3,709.2 ± 2,281.5 vs. 1,918.5 ± 1,140.6 ng/mL, <i>p</i> &#x3c; 0.001), NGAL (118.0 ± 70.3 vs. 91.8 ± 52.3 ng/mL, <i>p</i> = 0.003), and klotho (742.2 ± 497.4 vs. 470.3 ± 257.2 pg/mL, <i>p &#x3c;</i>0.001). Furthermore, the areas under the receiver operating curves demonstrated that serum cystatin C levels at admission had modest discriminative powers for predicting AKI after AMI compared with serum creatinine (0.899, 95% CI, 0.855–0.944 vs. 0.734, 95% CI, 0.649–0.819, <i>p &#x3c;</i>0.001). There was no difference between the discrimination performances of serum creatinine, NGAL, and klotho. <b><i>Conclusion:</i></b> Elevated cystatin C levels are associated with AKI in patients with AMI. This study provides reliable evidence that cystatin C levels may be superior to serum creatinine for predicting AKI after AMI at admission.

Sign in / Sign up

Export Citation Format

Share Document